Chiesi Farmaceutici identifies new DPP-1 inhibitors for NCFBE
Feb. 6, 2024
Chiesi Farmaceutici SpA has prepared azetidine derivatives acting as cathepsin C (dipeptidyl peptidase 1, DPP-1) inhibitors and reported to be useful for the treatment of non-cystic fibrosis bronchiectasis (NCFBE), among others.